<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453179</url>
  </required_header>
  <id_info>
    <org_study_id>X-03016-3284</org_study_id>
    <secondary_id>2010-022054-16</secondary_id>
    <nct_id>NCT01453179</nct_id>
  </id_info>
  <brief_title>Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)</brief_title>
  <acronym>LEIDA 2</acronym>
  <official_title>Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siro Clinpharm Germany GmbH (until June 2013)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accovion GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial serves the purpose to compare the long-term effects of a treatment of&#xD;
      actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3%&#xD;
      gel (Diclofenac) on the face or the scalp. In particular, it should be found out whether the&#xD;
      healing effect of these two medications on the skin lesions (i.e. the damaged skin parts) can&#xD;
      be maintained for a prolonged period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term outcome with respect to the risk of progression to SCC (in situ and/or invasive) of treatment with Aldara® 5% cream (IMIQ) and Solaraze® 3% gel (DIC) with increased precision (meta-analysis with study 3271).</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of rescue treatment</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>3 years</time_frame>
    <description>Cosmetic outcome assessed by patient and investigator on a verbal rating scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Aldara 5% Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solaraze 3% Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.</description>
    <arm_group_label>Aldara 5% Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.</description>
    <arm_group_label>Solaraze 3% Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible, a patient must comply with all of the following criteria:&#xD;
&#xD;
          -  Immunocompetent patient.&#xD;
&#xD;
          -  A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical&#xD;
             visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids,&#xD;
             the inside of the nostrils or ears, or the lip area inside the vermilion border must&#xD;
             not be part of this area.&#xD;
&#xD;
          -  A positive histological finding for AK grade I or II. This will be determined from the&#xD;
             most suspicious lesion in the STA and there from the most pathological area biopsied&#xD;
             during screening visit. This analysis will be done by the central histopathological&#xD;
             laboratory.&#xD;
&#xD;
          -  Willingness to comply with the obligations of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient is ineligible and must not enter the study if any of the following criteria is&#xD;
        met:&#xD;
&#xD;
        Safety concerns:&#xD;
&#xD;
          -  History of hypersensitivity to imiquimod, diclofenac, acetyl salicylic acid, other non&#xD;
             steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients.&#xD;
&#xD;
          -  Pregnancy, breast-feeding or planned pregnancy during the study. Women of child&#xD;
             bearing potential not using a highly effective method of birth control defined as&#xD;
             those which result in a low failure rate (i.e. &lt;1% per year) when used consistently&#xD;
             and correctly such as implants, injectables, combined oral contraceptives, hormonal&#xD;
             IUDs, tubal ligation or vasectomised partner.&#xD;
&#xD;
        Lack of suitability for the study:&#xD;
&#xD;
          -  Presence of AK lesions in the STA with clinically excessive hyperkeratosis as seen in&#xD;
             cutaneous horns.&#xD;
&#xD;
          -  Any topical AK treatment including imiquimod or diclofenac, or any systemic AK&#xD;
             treatment such as systemic retinoids, or any surgical AK treatment at the STA within&#xD;
             the last 2 months prior to randomisation.&#xD;
&#xD;
          -  Persisting AK lesion at screening visit following topical treatment with imiquimod or&#xD;
             diclofenac in the STA.&#xD;
&#xD;
          -  Presence of any histologically confirmed skin tumour in the STA: in situ SCC including&#xD;
             Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant tumours.&#xD;
&#xD;
          -  Any dermatological disease or condition that may exacerbate by treatment with&#xD;
             imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis).&#xD;
&#xD;
          -  Any dermatological disease or condition in the STA that causes difficulty with&#xD;
             examination (e.g. eczema).&#xD;
&#xD;
          -  Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine,&#xD;
             retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids&#xD;
             with dosages of &gt;1200 µg/day beclomethasone or equivalent within 4 weeks before start&#xD;
             of study treatment.&#xD;
&#xD;
          -  History of any malignant tumour with high tumour burden or any systemic antitumour&#xD;
             treatment (incl. radiotherapy).&#xD;
&#xD;
          -  History of any malignant skin tumour having metastasised or in which metastasis within&#xD;
             the study period is likely.&#xD;
&#xD;
          -  History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal,&#xD;
             haematological, endocrine, metabolic, mental, neurological, or other disease within&#xD;
             the last two years which might hinder regular treatment and supervision and might lead&#xD;
             to premature withdrawal from the study.&#xD;
&#xD;
          -  Mentally incapacitated patient.&#xD;
&#xD;
          -  Present or history of drug or alcohol abuse within the last 3 years.&#xD;
&#xD;
        Administrative reasons:&#xD;
&#xD;
          -  Exposure to an investigational product within the last 3 months.&#xD;
&#xD;
          -  Lack of ability or willingness to give informed consent.&#xD;
&#xD;
          -  Age below 18 years.&#xD;
&#xD;
          -  Lack of willingness to have personal study related data collected, archived or&#xD;
             transmitted according to protocol.&#xD;
&#xD;
          -  Anticipated non-availability for study visits/procedures.&#xD;
&#xD;
          -  Vulnerable subjects (such as persons kept in detention).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Petzold, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>MEDA Pharma GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Gollnick, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-von-Guericke-University of Magdeburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz, University Clinic for Dermatology and Venerology Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Maria Enzersdorf</city>
        <zip>A-2344</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Department for General Dermatology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Supply Center</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Licca Clinical Research Institute, Clinic for Dermatolgy and Surgery</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Berlin</city>
        <zip>D-10437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Duelmen</city>
        <zip>D-48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Germering</city>
        <zip>D-82110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venerology</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Mahlow</city>
        <zip>D-15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology Johannes Gutenberg-University Mainz, Clinical Research Center</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Markkleeberg</city>
        <zip>D-04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice for Dermatology and Medical Cosmetics</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>D-41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Münster</city>
        <zip>D-48143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Center Vechta, Clinic for Dermatology</name>
      <address>
        <city>Vechta</city>
        <zip>D-49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrovital, Medical Practice for Dermatology</name>
      <address>
        <city>Witten</city>
        <zip>D-58453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice for Dermatology and Venerology</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.euroderm.org</url>
    <description>European Dermatology Forum, Guidelines for the management of actinic keratoses. Last modified 26 Ocotober 2006.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actinic keratosis</keyword>
  <keyword>invasive SCC</keyword>
  <keyword>in situ SCC</keyword>
  <keyword>histological classification</keyword>
  <keyword>histological progression</keyword>
  <keyword>clinical clearance</keyword>
  <keyword>cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

